Anti-inflammatory effects of orally administered glucosamine oligomer in an experimental model of inflammatory bowel disease

被引:67
作者
Azuma, Kazuo [1 ]
Osaki, Tomohiro [1 ]
Kurozumi, Seiji [2 ]
Kiyose, Masatoshi [2 ]
Tsuka, Takeshi [1 ]
Murahata, Yusuke [1 ]
Imagawa, Tomohiro [1 ]
Itoh, Norihiko [1 ]
Minami, Saburo [1 ]
Sato, Kimihiko [2 ]
Okamoto, Yoshiharu [1 ]
机构
[1] Tottori Univ, Sch Vet Med, Dept Vet Clin Med, Tottori 6808553, Japan
[2] Koyo Chem Co Ltd, Chiyoda Ku, Tokyo 1020072, Japan
关键词
Glucosamine oligomers; Inflammatory bowel disease; Anti-inflammatory; Functional food; Nuclear factor-kappa B; SODIUM-INDUCED COLITIS; NF-KAPPA-B; NITRIC-OXIDE; ULCERATIVE-COLITIS; CHITIN NANOFIBRILS; EPITHELIAL-CELLS; MECHANISMS; ANTITUMOR; MICE; CHITOOLIGOSACCHARIDES;
D O I
10.1016/j.carbpol.2014.09.012
中图分类号
O69 [应用化学];
学科分类号
070301 [无机化学];
摘要
Anti-inflammatory effects of oral administration of the glucosamine oligomers (chito-oligosaccharides: COS) were evaluated in an experimental model of inflammatory bowel disease (IBD). Oral administration of COS improved shortening of colon length and tissue injury (as assessed by histology) in mice. Oral administration of COS inhibited inflammation in the colonic mucosa by suppression of myeloperoxidase activation in inflammatory cells, as well as activation of nuclear factor-kappa B, cyclooxygenase-2, and inducible nitric oxide synthase. Oral administration of COS also reduced serum levels of pro-inflammatory cytokines (tumor necrosis factor-alpha and interleukin-6). Moreover, it prolonged survival time in mice. These data suggest that COS have anti-inflammatory effects in an experimental model of IBD, and could be new functional foods for IBD patients. (C) 2014 Elsevier Ltd. All rights reserved.
引用
收藏
页码:448 / 456
页数:9
相关论文
共 38 条
[1]
Araujo Leila Fernandes, 2005, Arq. Bras. Cardiol., V85, P222
[2]
α-Chitin nanofibrils improve inflammatory and fibrosis responses in inflammatory bowel disease mice model [J].
Azuma, Kazuo ;
Osaki, Tomohiro ;
Ifuku, Shinsuke ;
Saimoto, Hiroyuki ;
Tsuka, Takeshi ;
Imagawa, Tomohiro ;
Okamoto, Yoshiharu ;
Minami, Saburo .
CARBOHYDRATE POLYMERS, 2012, 90 (01) :197-200
[3]
Beneficial and preventive effect of chitin nanofibrils in a dextran sulfate sodium-induced acute ulcerative colitis model [J].
Azuma, Kazuo ;
Osaki, Tomohiro ;
Wakuda, Takashi ;
Ifuku, Shinsuke ;
Saimoto, Hiroyuki ;
Tsuka, Takeshi ;
Imagawa, Tomohiro ;
Okamoto, Yoshiharu ;
Minami, Saburo .
CARBOHYDRATE POLYMERS, 2012, 87 (02) :1399-1403
[4]
Potential for Amino Acids Supplementation During Inflammatory Bowel Diseases [J].
Coeffier, Moiese ;
Marion-Letellier, Rachel ;
Dechelotte, Pierre .
INFLAMMATORY BOWEL DISEASES, 2010, 16 (03) :518-524
[5]
Nitric oxide in inflammatory bowel disease [J].
Cross, RK ;
Wilson, KT .
INFLAMMATORY BOWEL DISEASES, 2003, 9 (03) :179-189
[6]
Experimental models of inflammatory bowel disease reveal innate, adaptive, and regulatory mechanisms of host dialogue with the microbiota [J].
Elson, CO ;
Cong, Y ;
McCracken, VJ ;
Dimmitt, RA ;
Lorenz, RG ;
Weaver, CT .
IMMUNOLOGICAL REVIEWS, 2005, 206 :260-276
[7]
Inflammatory bowel disease: A survey of the epidemiology in Asia [J].
Goh, K. L. ;
Xiao, Shu-Dong .
JOURNAL OF DIGESTIVE DISEASES, 2009, 10 (01) :1-6
[8]
Nitric oxide and chronic gut inflammation: Controversies in inflammatory bowel disease [J].
Grisham, MB ;
Pavlick, KP ;
Laroux, FS ;
Hoffman, J ;
Bharwani, S ;
Wolf, RE .
JOURNAL OF INVESTIGATIVE MEDICINE, 2002, 50 (04) :272-283
[9]
THE SELECTIVE BENEFICIAL-EFFECTS OF NITRIC-OXIDE INHIBITION IN EXPERIMENTAL COLITIS [J].
HOGABOAM, CM ;
JACOBSON, K ;
COLLINS, SM ;
BLENNERHASSETT, MG .
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY, 1995, 268 (04) :G673-G684
[10]
Strong electronic charge as an important factor for anticancer activity of chitooligosaccharides (COS) [J].
Huang, R ;
Mendis, E ;
Rajapakse, N ;
Kim, SK .
LIFE SCIENCES, 2006, 78 (20) :2399-2408